Literature DB >> 12773653

Fusion inhibition--a major but costly step forward in the treatment of HIV-1.

Karen T Tashima, Charles C J Carpenter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12773653     DOI： 10.1056/NEJMe030042

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.

Authors:  Myriam Witvrouw; Valery Fikkert; Anke Hantson; Christophe Pannecouque; Barry R O'keefe; James McMahon; Leonidas Stamatatos; Erik de Clercq; Anders Bolmstedt
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.

Authors:  Jörg Ruof; Alexander Dusek; Michael DeSpirito; Ralph A Demasi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.

Authors:  Wenjie Ouyang; Tai An; Deyin Guo; Shuwen Wu; Po Tien
Journal:  AIDS Res Hum Retroviruses       Date:  2013-01-11       Impact factor: 2.205

4.  Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.

Authors:  Marianne Harris; Bohdan Nosyk; Richard Harrigan; Viviane Dias Lima; Calvin Cohen; Julio Montaner
Journal:  AIDS Res Treat       Date:  2012-11-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.